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Background and Purpose  GNE myopathy is a rare progressive myopathy caused by biallelic 
mutations in the GNE gene, and frequently accompanied by rimmed vacuoles in muscle pa-
thology. The initial symptom of foot drop or hip-girdle weakness eventually spreads to all limbs 
over a period of decades. Recent advances in pathophysiologic research have facilitated thera-
peutic trials aimed at resolving the core biochemical defect. However, there remains unsettled 
heterogeneity in its natural course, which confounds the analysis of therapeutic outcomes. We 
performed the first large-scale study of Korean patients with GNE myopathy.
Methods  We gathered the genetic and clinical profiles of 44 Korean patients with genetically 
confirmed GNE myopathy. The clinical progression was estimated retrospectively based on a 
patient-reported questionnaire on the status of the functional joint sets and daily activities. 
Results  The wrist and neck were the last joints to lose antigravity functionality irrespective of 
whether the weakness started from the ankle or hip. Two-thirds of the patients could walk either 
independently or with an aid. The order of losing daily activities could be sorted from standing 
to eating. Patients with limb-girdle phenotype showed an earlier age at onset than those with 
foot-drop onset. Patients with biallelic kinase domain mutations tended to progress more rap-
idly than those with epimerase and kinase domain mutations.
Conclusions  The reported data can guide the clinical management of GNE myopathy, as well 
as provide perspective to help the development of clinical trials
Key Words   nonaka type distal myopathy, limb-girdle muscular dystrophies, 
disease progression, mutation, surveys and questionnaires.
Progression of GNE Myopathy Based 
on the Patient-Reported Outcome
INTRODUCTION
GNE myopathy is a muscle disease caused by biallelic recessive mutations in the gene en-
coding UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE).1 It 
encompasses all of the previously described terms of distal myopathy with rimmed vacu-
oles, Nonaka myopathy, hereditary inclusion body myopathy, and inclusion body myopa-
thy type.2 The term GNE myopathy was proposed as being more appropriate for unifying 
all of the above myopathic conditions related to GNE mutations.2 
GNE myopathy starts during adulthood, most frequently in the third decade, and initially 
involves distal leg muscles, with slow progression to the proximal legs and upper limbs.2 
Cardiac and respiratory functions are typically spared. Some cases present with proximal 
leg weakness,3,4 finger weakness,5 or calf atrophy.4 Rimmed vacuoles on muscle pathology 
are a clue for a diagnosis of GNE myopathy, while it is not detected in all cases of genetically 
confirmed GNE myopathy. We have previously reported that a significant number of pa-
tients present with limb-girdle weakness, with some patients not having rimmed vacuoles 
in muscle biopsies.3 The quadriceps muscles are usually spared even in the advanced stages, 
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frequently exhibiting normal or minimal histopathology.
More than 150 pathogenic GNE mutations have been de-
tected, most of which are missense mutations dispersed over 
the entire length of the GNE gene.6 Some mutations appear at 
higher frequency in certain ethnic groups, including p.Met743 
Thr in Iranian Jewish patients and p.Val603Leu in Japanese 
patients.7 
Supplementing intermediate metabolites of the sialic acid 
pathway including sialic acid, sialyllactose, and ManNAc has 
shown promising results in preclinical studies.8 Unfortunate-
ly, the extended-release form of sialic acid failed to show ef-
fectiveness in the phase 3 clinical trial (clinicaltrials.gov: NCT 
02377921), indicating a gap in the translation of the success 
in mice to humans. Clinical trial using ManNAc as an oral 
agent are currently underway.9 
Clinical profiling and determining the natural history are 
more important than ever for maximizing the confidence in 
a clinical trial. In the present study we analyzed the clinical 
and genetic profiles of Korean patients with genetically con-
firmed GNE myopathy. We also investigated the correlations 
between clinical features, mutations, and disease severity. 
METHODS
Patients
This study included 44 patients (19 males and 25 females) 
with homozygous or compound heterozygous GNE muta-
tions, most of which were previously reported as pathogen-
ic ones and others were predicted as being ‘damaging’ by in 
silico analyses, and also classified as ‘pathogenic’ or ‘likely 
pathogenic’ according to the American College of Medical 
Genetics and Genomics and the Association for Molecular 
Pathology (ACMG/AMP) guideline.10 All of the recruited 
patients agreed to provide their medical records, complete 
clinical questionnaires, and provide written informed consent. 
The Institutional Review Board of Pusan National University 
Hospital approved this study (IRB No. H-1712-002-061).
GNE mutation data
All of the included patients had confirmed pathogenic GNE 
mutations in nine different hospitals with neuromuscular 
specialists prior to recruitment to this study. We extracted 
DNA from the whole blood of 15 of the patients who direct-
ly visited our neuromuscular center, which was used in 
PCR amplification and direct sequence analyses in our labo-
ratory. The PCR amplification covered all 12 exons and the 
immediately flanking intronic regions of the GNE gene. The 
PCR products were sequenced in both the forward and re-
verse directions. Sequences were analyzed and compared with 
the reference sequence (GenBank accession number NM_ 
001128227.2). Seven of the patients who were genetically di-
agnosed in other hospitals personally provided their medi-
cal records, including mutation data. For the remaining 22 
patients who could not acquire their mutational reports from 
their hospitals, GNE tests were performed at the laboratory of 
EGL Genetics (Tucker, GA, USA). 
Functional status
We applied a questionnaire-based survey to determine the 
functional status of the patients. Most of the information was 
collected using a self-reporting questionnaire, but we also 
retrospectively reviewed any available hospital records for 
further information. The questionnaire included inquiries 
on the following features: age at disease onset, initial presenta-
tion symptoms, mode of ambulation, and time of losing am-
bulation. In addition, we asked how many of the following 
eight major joint movements of the body could be performed 
against gravity: shoulder abduction, elbow flexion, wrist 
flexion/extension, hip flexion, knee extension, ankle dorsi-
flexion, neck flexion when supine, and trunk flexion when 
supine. Patients were asked whether they were independent 
or dependent on caregivers when performing major activi-
ties of daily living, including standing from a squatting posi-
tion, getting up from the bed, eating, cleaning the face, going 
to the toilet, and changing clothes. 
Statistical analyses
Linear regression analysis was applied to the relationships 
between disease duration and joints with mobility against 
gravity, and between disease duration and independent daily 
activities. Subjects capable of either all or none of the func-
tional movements and daily activities were excluded from 
the analysis in order to prevent the ceiling effect. We further 
evaluated the disease progression depending on the initial 
symptoms or the domains of GNE mutations. These subgroup 
analyses were performed using Student’s t-test or one-way 
ANOVA. A p value of <0.05 was considered to be indicative 
of statistically significant data. 
RESULTS
General characteristics
The clinical information of the 44 Korean patients from 41 
families is provided in Table 1. Their age at the time of data 
collection was 36.0±10.7 years (mean±SD). Their age at on-
set ranged from 14 to 51 years (26.3±9.2 years), and patient 
16-II was an asymptomatic brother of patient 16-I. The dis-
ease duration from onset to diagnosis was 1–41 years (10.0± 
8.8 years). Eleven of the patients had affected siblings compat-
ible with an autosomal recessive inheritance pattern. None of 
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the patients with a detailed family history reported obvious 
consanguinity. 
GNE mutations
All of the recruited patients harbored homozygous or com-
pound heterozygous GNE mutations. The types of mutations 
and their locations and frequencies are presented in Table 1 and 
Fig. 1. The most common mutation was c.1807G>C (p.Val-
603Leu), which was found in 45 alleles (51.1%), followed by 
c.131G>C (p.Cys44Ser) found in 20 alleles (22.7%). Homo-
zygosity was also related to these two common mutations, 
and was found in 11 patients with p.Val603Leu and 3 with 
p.Cys44Ser. Two of the 15 different mutations have not been 
reported elsewhere. One of the novel mutations (c.1619A> C, 
p.His540Pro) was predicted to be ‘damaging’ and ‘disease 
causing’ by in silico analyses implemented using PROVEAN 
(http://provean.jcvi.org) and MutationTaster (http://mutation-
taster.org), and classified as ‘likely pathogenic’ according to 
the ACMG/AMP guideline, since a change in the same amino 
acid by a different nucleotide change (c.1618C>T, p.His540Tyr) 
is reportedly pathogenic.11 The second one (c.2046delT, p.Val 
684Leufs*2) can be classified as ‘pathogenic’ since it is ex-
pected to cause premature termination by frameshift. The 
other 13 mutations were first reported in Korean, Japanese, 
or Chinese patients.6 Except for 3 frameshift mutations in-
volving small deletions, 12 were all missense mutations. No 
case had truncating mutations in both alleles. The muta-
tions were scattered throughout the exons. Eight of the mu-
tations were located in the epimerase domain (ED) and the 
other seven were in the kinase domain (KD), as presented in 
Fig. 1. Both mutations were present in KD in 17 of the pa-
tients (38.6%), while both were in ED in 5 patients (11.4%). 
The other 22 patients (50.0%) had one mutation in each do-
main (ED/KD). 
Presenting symptoms; initially affected muscle 
groups
Various initial symptoms at disease onset were reported by 
the patients, as indicated in Table 1. Foot drop and/or big-
toe extension weakness indicating affected anterior lower 
leg muscles was reported in 19 of the patients (43.2%). Thir-
teen patients (29.5%) reported running or climbing difficul-
ty suggestive of hip-girdle weakness as their first symptom. 
Six of the patients (13.6%) described difficulty in toe gait or 
calf atrophy corresponding to the posterior lower legs being 
affected. One exceptional patient reported weak thumb flex-
ion as his first symptom. Patient 16-II remained asymptom-
atic until the last follow-up at an age of 19 years. The remain-
ing four patients recalled experiencing nonspecific symptoms 
(e.g., buttock pain or gait disturbance) at the beginning of Ta
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their disease. 
Among 20 patients for whom medical records on the initial 
symptoms were available, 12 described having more promi-
nent weakness in ankle dorsiflexion. Meanwhile, disturbed 
toe gait and/or calf muscle atrophy was reported in two of the 
patients, while proximal dominant leg weakness was described 
in the other four.
Decrease in the number of functional joints
We considered a set of joints to be functional when the pa-
tient could flex or extend the joint against gravity. Fig. 2A de-
picts the pattern of loss of functional joint movement. Ankle 
dorsiflexion was the most commonly affected movement 
when the patient had just begun to lose a single functional set 
of joints. On the other hand, wrist or neck flexion was most 
likely to be the last functional movement that was lost.
All 8 sets of joint movements remained functional in 12 of 
the patients, and their disease duration was 2–7 years (4.2± 
2.2 years). Seven patients had no functionality in any of the 
eight considered joint movements, and their disease duration 
was 11–41 years (23.3±10.7 years). The number of function-
al joint sets was strongly correlated with the disease dura-
tion, as shown by the results of the linear regression analysis 
in Fig. 2B (r2=0.5228, p<0.0001) reflecting the progression 
of GNE myopathy. The mean yearly rate of decrease in the 
number of functional joint sets was -0.2581, with a 95% CI of 
-0.1517 to -0.3645. 
Ambulation
Sixteen patients (36.4%) had to use wheelchairs throughout 
the day, 20 patients (45.5%) were still capable of completely 
independent ambulation, and 8 patients (18.1%) used walk-
ing aids when walking longer distances. The self-reported dis-
ease duration to a wheelchair-bound state was 10.6±3.3 years 
(5–15 years). There was a clear difference in the disease dura-
tion between ambulatory and wheelchair-bound patients, at 
4.5±0.7 years (1–13 years) and 17.4±2.2 years (9–41 years), 
respectively (Fig. 3A). 
Functional status during daily activities 
The daily activities that each patient could perform inde-
pendently are listed in Fig. 3B, sorted in decreasing numer-
ical order. Among 41 patients who provided information 
on their independent daily activities, 21 (51.2%) were could 
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still independently perform all six kinds of the activities 
surveyed. Standing from a squatting position was disturbed 
at the earliest time point, which was lost in all five patients 
who could still perform the other five activities. The disease 
duration of these patients was 6–10 years (7.8±1.6 years). 
After standing from a squatting position, the order of in-
dependent activities lost were getting up from the bed, chang-
ing clothes, and going to the toilet, all of which require move-
ments of both the upper and lower extremities. Cleaning the 
face and eating, which mainly involve the upper extremities, 
were the last activities to be disturbed. Eight patients (19.5%) 
could perform none of the activities at all, and they had a 
disease duration of 11–41 years (24.0±10.1 years). The rela-
tionship between disease duration and independent activi-
ties is depicted in Fig. 3C (r2=0.4841, p=0.012). 
Disease severity according to types of initial 
symptoms
The age at onset was markedly younger in the subgroup with 
limb-girdle phenotype (23.2±1.6 years) than in that with foot 
drop onset (31.2±2.0 years, p=0.006; Fig. 4A). The duration 
from the onset to the diagnosis was significantly longer in the 
subgroup with limb-girdle (5.1±0.9 vs. 11.1±2.6 years, p= 
0.0186), as shown in Fig. 4B.
The yearly rates of loss of functional joints were -0.3008 
(r2=0.5827, p=0.0015) and -0.2901 (r2=0.8893, p=0.0162) in 
the subgroups of foot drop and limb-girdle respectively, with 
no significant difference (p=0.5731) (Fig. 4C and D). 
Disease severity according to domains of GNE 
mutations
We compared the disease severity among subgroups accord-
ing to domains where the mutations were located; that is, the 
KD, ED/KD, and ED subgroups. The age at onset did not 
differ significantly among these subgroups (p=0.387) (Fig. 
5A). On the other hand, the decrease ratios of functional joints 
did differ significantly among the three subgroups (p=0.0062, 
Fig. 5B–D), with a mean decrease ratio of -0.3617 in KD (r2= 
0.7234, p=0.0037), -0.2601 in ED/KD (r2=0.4403, p=0.0186), 
and -0.1402 in ED (r2=0.8760, p=0.0641). The disease dura-
tion among wheelchair-bound patients did not differ signifi-
cantly between the two subgroups of KD (17.5±3.6 years, 
n=8) and ED/KD (15.9±3.4 years, n=8; p=0.7455). The ED 
subgroup was excluded from this analysis due to the small 
number of wheelchair-dependent subjects (n=3). 
Fig. 3. Functional status during ambulation and daily activities. A: The disease duration clearly differed between the ambulatory and wheelchair-
bound patients, at 4.5±0.7 and 17.4±2.2 years, respectively. B: All of the daily activities that could be performed independently by each of the pa-
tients. C: The number of independent daily activities was correlated with the disease duration (p=0.012). ADL: activities of daily living.
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DISCUSSION
This study included 44 Korean patients with GNE myopa-
thy who agreed to submit their genetic report biallelic GNE 
mutations. The missense mutation p.Val603Leu was the 
most common pathogenic allele (51.1%), followed by 
p.Cys44Ser (22.7%). The most frequent genotypes were ho-
mozygous p.Val603Leu (n=11) and the compound hetero-
zygotes of p.Val603Leu and p.Cys44Ser (n=9). These find-
ings are consistent with those of previous studies of Korean 
patients with GNE myopathy.3,12,13 Although known GNE 
mutations are scattered throughout the gene, these two vari-
ants comprise more than half of all cases. These mutations 
also appear very frequently in Japanese patients, correspond-
ing to the first and third most common mutations.14 Four of 
the mutations in the present study have been reported only 
in Korean patients with GNE myopathy,3,13 and the remain-
ing ones are shared with Japanese and/or Chinese cases.6 
However, the mutation of p.Asp207Val, which is the second 
most common mutation in Japanese patients, was detected 
among a smaller proportion (6.8%) of our cohort, and p.
Val603Leu has been found in only a few Chinese patients.15 
The homozygosity found in 14 patients either with p.Val-
603Leu and p.Cys44Ser was not related to consanguinity ac-
cording to the best knowledge of the patients; marriage to a 
third cousin or closer relative is prohibited both culturally 
and legally in Korea. The allele frequencies of the two most 
common variants estimated by homozygosity are 0.046% 
and 0.024%. The allele frequency of the p.Val603Leu variant 
reported by the Exome Aggregation Consortium is 0.034% 
(3/8, 654) in East Asians.
Clinical profiles were analyzed with the aid of a question-
naire-based survey and complemented by reviewing the avail-
able medical records. The general findings from our question-
naire survey were comparable to those obtained from the 
analysis of the medical records and registry data. The onset 
age of our patients was similar to that in another Korean co-
hort (23.8±8.8 years),13 a Japanese cohort (25.2±9.2 years),16 
Fig. 4. Disease severity according to the types of initial symptoms. A: The onset age was significantly younger in the subgroup with limb-girdle 
phenotype. B: The duration from the onset to the diagnosis was significantly longer in the subgroup with limb-girdle phenotype. C and D: Disease 
progression as represented by the functional joint sets according to disease duration did not differ between the subgroups of foot-drop onset and 
limb-girdle phenotype (p=0.5731).
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and a recent global study involving subjects with various 
ethnic backgrounds (mean 27.8 years).17 In terms of age at 
data collection, one Japanese cohort included older patients 
(age 43.1±10.7 years), probably with a longer disease dura-
tion,18 and our patients (age 36.0±10.7 years) were as old as 
those in the recent global study (mean ages of 38.7 years in 
males and 39.5 years in females).17 The disease duration from 
onset to the time of using wheelchair was slightly shorter in 
our cohort (10.6±3.3 years) than in the other studies (11.5±1.2 
years in Japan and a mean of 11.9 years in the global study),17,18 
which may have been due to the national support program for 
assistance devices in Korea.
Compared to our previous report on 11 patients,3 a smaller 
proportion of the present patients reported proximal leg 
weakness as their first symptom, while it was significantly 
larger than previously estimated. A particularly interesting 
observation was that two patients in this cohort lost all func-
tional movements in the hip, neck, and trunk prior to expe-
riencing weakness in ankle dorsiflexion. Some patients pre-
sented with atypical patterns of weakness, such as toe-gait 
difficulty and finger weakness. These findings support the 
presence of heterogeneity in the clinical course of GNE my-
opathy, which clinicians should be aware of during the diag-
nostic process of genetic myopathies. 
The patient-reported functional status as represented by 
the number of functional limb movements and independent 
daily activities showed a strong correlation with the disease 
progression in the present study. A recent study also found 
that patient-reported outcomes were valid and reliable mea-
sures of physical function in GNE myopathy.19 According to 
a previous report on the GNE Myopathy Functional Activity 
Scale (GNEM-FAS), which was developed for clinical re-
search and trials,20 mobility, upper extremity function, and 
independent activities of daily living were most affected by 
the disease progression in GNE myopathy patients. Our ques-
tionnaire included items that were scored on the GNEM-
FAS, although we did not quantify motor power in the upper 
or lower extremities. Counting the number of functional 
Fig. 5. Disease severity according to the domains of GNE mutations. A: The onset age did not differ significantly among the three subgroups of 
KD, ED/KD, and ED. B–D: Disease progression as represented by the number functional joint sets according to disease duration significantly rapid 
in the order of KD (B), ED/KD (C), and ED (D) (p=0.0062). ED: epimerase domain, KD: kinase domain.
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limb movements and the activities of daily living—as in the 
present study—are useful methods for assessing the func-
tional status. 
Our results reveal marked deteriorations in functional limb 
movements and daily activities over a disease duration of 
10 to 20 years. These data will facilitate predictions of the 
order of increasing disabilities, and thereby guide patients 
and their caregivers to plan ahead. During the first decade of 
disease onset, ankle dorsiflexion and standing from a squat-
ting position were the most frequently affected movements. 
Wrist and neck flexion as well as the activities of the upper 
extremities such as cleaning the face and eating were pre-
served up to the most advanced stages. The patients lost all 
of their functional joints and became fully dependent on 
caregivers for daily living at 30 years after the onset. Patients 
with limb-girdle weakness had an earlier onset and a more-
delayed diagnosis compared to those with foot-drop onset. 
However, we did not see a significant difference in the rate 
of progression.
GNE is a distinctively bifunctional enzyme, and the posi-
tion of GNE mutations may influence the phenotype. In our 
subgroup analyses, the age at onset did not differ among the 
KD, ED/KD, and ED subgroups. However, disease progres-
sion as represented by the decrease in the ratio of functional 
joints was significantly more rapid in the KD group than in 
the ED/KD and ED groups. One Japanese and another Chi-
nese report also described that patients with heterozygous 
ED/KD mutations show a less severe phenotype,15,18 while 
another report on patients with various ethnic backgrounds 
demonstrated that the ED/KD genotype tended to be asso-
ciated with the lowest proportion of ambulatory patients, 
earliest onset, and earliest use of a wheelchair.17 That report 
pointed that p.Asp207Val, which is known to be a milder 
mutation, was predominant in Japanese and Chinese cohorts, 
and possibly obscured the final analysis. However, it is unlikely 
that our results were affected by the mild p.Asp207Val mu-
tation, since our cohort included far fewer patients with p.
Asp207Val. Thus, the present study reinforces that the ED/
KD genotype, which theoretically involves each allele com-
pensating for the other, is related to a less severe phenotype. 
In conclusion, this study has revealed the genetic and clini-
cal characteristics in a Korean cohort of GNE myopathy, es-
pecially in relation to the disease severity and progression. 
This is the first large-scale report on Korean GNE myopathy, 
and it has provided basic data on the natural course of GNE 
myopathy, which will be helpful not only for managing care 
but also for designing future clinical trials. A limitation of 
this study is its retrospective analysis based on self-reporting 
questionnaires. Future prospective monitoring of disease se-
verity with quantitative measurements will provide less bi-
ased insight into the natural course. 
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